143 related articles for article (PubMed ID: 37133554)
1. Cost-effectiveness of an urinary biomarker panel in combination with MRI for prostate cancer diagnosis.
Govers TM; Resnick MJ; Rastinehad AR; Caba L; Groskopf J; van Criekinge W
World J Urol; 2023 Jun; 41(6):1527-1532. PubMed ID: 37133554
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study.
Govers TM; Hessels D; Vlaeminck-Guillem V; Schmitz-Dräger BJ; Stief CG; Martinez-Ballesteros C; Ferro M; Borque-Fernando A; Rubio-Briones J; Sedelaar JPM; van Criekinge W; Schalken JA
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):101-109. PubMed ID: 30127462
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model.
Dijkstra S; Govers TM; Hendriks RJ; Schalken JA; Van Criekinge W; Van Neste L; Grutters JPC; Sedelaar JPM; van Oort IM
BJU Int; 2017 Nov; 120(5):659-665. PubMed ID: 28370948
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Urinary Biomarker Panel in Prostate Cancer Risk Assessment.
Govers TM; Caba L; Resnick MJ
J Urol; 2018 Dec; 200(6):1221-1226. PubMed ID: 30012363
[TBL] [Abstract][Full Text] [Related]
5. Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis.
Sathianathen NJ; Kuntz KM; Alarid-Escudero F; Lawrentschuk NL; Bolton DM; Murphy DG; Weight CJ; Konety BR
J Urol; 2018 Dec; 200(6):1215-1220. PubMed ID: 29906434
[TBL] [Abstract][Full Text] [Related]
6. Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men.
Hendriks RJ; van der Leest MMG; Israël B; Hannink G; YantiSetiasti A; Cornel EB; Hulsbergen-van de Kaa CA; Klaver OS; Sedelaar JPM; Van Criekinge W; de Jong H; Mulders PFA; Crawford ED; Veltman J; Schalken JA; Barentsz JO; van Oort IM
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1110-1119. PubMed ID: 33941866
[TBL] [Abstract][Full Text] [Related]
7. A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection.
Hendriks RJ; van der Leest MMG; Dijkstra S; Barentsz JO; Van Criekinge W; Hulsbergen-van de Kaa CA; Schalken JA; Mulders PFA; van Oort IM
Prostate; 2017 Oct; 77(14):1401-1407. PubMed ID: 28853167
[TBL] [Abstract][Full Text] [Related]
8. Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer.
Visser WCH; de Jong H; Steyaert S; Melchers WJG; Mulders PFA; Schalken JA
Prostate Cancer Prostatic Dis; 2022 Sep; 25(3):583-589. PubMed ID: 35810263
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective.
de Rooij M; Crienen S; Witjes JA; Barentsz JO; Rovers MM; Grutters JP
Eur Urol; 2014 Sep; 66(3):430-6. PubMed ID: 24377803
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: a systematic review and diagnostic meta-analysis.
Sari Motlagh R; Yanagisawa T; Kawada T; Laukhtina E; Rajwa P; Aydh A; König F; Pallauf M; Huebner NA; Baltzer PA; Karakiewicz PI; Heidenreich A; Shariat SF
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):187-198. PubMed ID: 35414118
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation.
Mowatt G; Scotland G; Boachie C; Cruickshank M; Ford JA; Fraser C; Kurban L; Lam TB; Padhani AR; Royle J; Scheenen TW; Tassie E
Health Technol Assess; 2013 May; 17(20):vii-xix, 1-281. PubMed ID: 23697373
[TBL] [Abstract][Full Text] [Related]
12. Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States.
Jiao B; Gulati R; Hendrix N; Gore JL; Rais-Bahrami S; Morgan TM; Etzioni R
Value Health; 2021 Aug; 24(8):1111-1117. PubMed ID: 34372976
[TBL] [Abstract][Full Text] [Related]
13. Active Surveillance Strategies for Low-Grade Prostate Cancer: Comparative Benefits and Cost-effectiveness.
Kang SK; Mali RD; Prabhu V; Ferket BS; Loeb S
Radiology; 2021 Sep; 300(3):594-604. PubMed ID: 34254851
[TBL] [Abstract][Full Text] [Related]
14. Can the predictive value of multiparametric MRI for prostate cancer be improved by a liquid biopsy with SelectMDx?
Rahnama'i MS; Bach C; Schulze-Hagen M; Kuhl CK; Vögeli TA
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1396. PubMed ID: 33931984
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of multiparametric magnetic resonance imaging and MRI-guided biopsy in a population-based prostate cancer screening setting using a micro-simulation model.
Getaneh AM; Heijnsdijk EA; de Koning HJ
Cancer Med; 2021 Jun; 10(12):4046-4053. PubMed ID: 33991077
[TBL] [Abstract][Full Text] [Related]
16. Concordance and Performance of 4Kscore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer.
Wysock JS; Becher E; Persily J; Loeb S; Lepor H
Urology; 2020 Jul; 141():119-124. PubMed ID: 32294481
[TBL] [Abstract][Full Text] [Related]
17. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
[TBL] [Abstract][Full Text] [Related]
18. Beyond blood biomarkers: the role of SelectMDX in clinically significant prostate cancer identification.
Ferro M; Rocco B; Maggi M; Lucarelli G; Falagario UG; Del Giudice F; Crocetto F; Barone B; La Civita E; Lasorsa F; Brescia A; Catellani M; Busetto GM; Tataru OS; Terracciano D
Expert Rev Mol Diagn; 2023; 23(12):1061-1070. PubMed ID: 37897252
[TBL] [Abstract][Full Text] [Related]
19. A SelectMDx/magnetic resonance imaging-based nomogram to diagnose prostate cancer.
Wagaskar VG; Levy M; Ratnani P; Sullimada S; Gerenia M; Schlussel K; Choudhury S; Gabriele M; Haas I; Haines K; Tewari A
Cancer Rep (Hoboken); 2023 Jan; 6(1):e1668. PubMed ID: 36168681
[TBL] [Abstract][Full Text] [Related]
20. Multiparametric MRI
Pepe P; Dibenedetto G; Pepe L; Pennisi M
In Vivo; 2020; 34(1):393-396. PubMed ID: 31882504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
